cyrilzakka/clinical-trials huggingface dataset:
The KinematX Midcarpal Total Wrist Arthroplasty Registry

The goal of this observational study is to learn about functional and patient reported outcomes in patient undergoing total wrist replacement with the KinematX total wrist replacement study.

The main questions it aims to answer are:

* What is the range of motion (flexion, extension, radial, ulnar, grip and pinch strength) at 3-, 6-, and 12-months after surgery and yearly up to 10 years among patients having total wrist replacement with the KinematX implant.
* What are the patient reported outcomes (PROMIS, PRWE, HSS wrist expectations) at 3-, 6-, and 12-months after surgery and yearly up to 10 years among patients having total wrist replacement with the KinematX implant.
* How do range of motion and patient reported outcomes change over the 10 years after total wrist replacement surgery?

Participants will be followed according to standard of care and preoperative and post-operative information for up to 10 years after surgery will be collected and entered into an electronic data base. Patients are eligible to enroll into the registry before or after they have had their wrist replacement surgery.


Eligibility Criteria:
Inclusion Criteria:

* one of the following diagnoses and planned (or previously completed) total wrist arthroplasty with the KinematX total wrist:

  * osteoarthritis or post-traumatic arthritis
  * scapholunate advanced collapse (SLAC/SNAC wrist),
  * inflammatory arthritis (rheumatoid, psoriatic, other),
  * crystalline advanced collapse (SCAC),
  * STT advanced collapse (STTAC),
  * ulnar translocation,
  * Kienbӧck disease,
  * radial malunion

Exclusion Criteria:

* \<18 years of age
* \>85 years of age
* Prisoners
* Children
* Pregnant women
* Contraindications to receiving the KinematX:

  * Local, distant or systematic acute or chronic soft tissue or bony infection
  * Physiologically or psychologically compromised patient
  * Active wrist synovitis or severe carpal bone erosion
  * Suspected or documented metal allergy or intolerance
  * Insufficient extensor tendons
  * Inadequate skin, bone, neural or vascular status
  * Severe carpal bone malalignment, displacement, absorption, neoplastic, or carpal bone pathology
  * Sepsis
  * Osteomyelitis
  * Uncontrolled/untreated osteoporosis or metabolic bone disease
  * Metabolic or endocrinologic bone disorders
  * Osteomalacia
  * Distant foci of infections which may spread to the implant site
  * Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram
The Effect of Subcutaneous and Intraperitoneal Anesthesia on Post Laparoscopic Pain

Aim of this study is to examine the effects of subcutaneously applied local anesthetics at trocar site in combination with intraoperative intraperitoneal analgesia on duration and character of pain in pediatric patients undergoing laparoscopic varicocelectomy.


Eligibility Criteria:
Inclusion Criteria:

* pediatric patients with varicocele who underwent laparoscopic varicocelectomy
* pediatric patients whose parents or guardians gave informed consent

Exclusion Criteria:

* patients who received open or microsurgical varicocelectomy
* pediatric patients who underwent conversion to open procedure
* pediatric patients with chronic, metabolic and endocrine diseases
* pediatric patients with systemic infections
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid

This study was designed to be a retrospective, multicentre, observational study to evaluate the efficacy and safety of dupilumab in the treatment of bullous pemphigoid and to find predictors of efficacy.


Eligibility Criteria:
Inclusion Criteria:

* Adult bullous pemphigoid patients treated with dupilumab between January 1, 2021, and July 31, 2022, at six leading dermatology departments in the Chinese Collaborative Network for Autoimmune Bullous Diseases.
* The diagnosis of BP requires clinical manifestations and immunological or pathological evidences.
* Dupilumab treatment should continue for at least 4 weeks and possibly longer.

Exclusion Criteria:

* Drug-induced BP, γ-1 pemphigoid
* Patients with less than 4 weeks of follow-up
* Patients were given any other biologicals within 6 months before the first dupilumab administration
Post-exercise Insulin Reductions in Type 1 Diabetes

The investigators hypothesise that reducing rapid-acting insulin dose after exercise will help prevent Type 1 diabetes individuals experiencing hypoglycaemia.


Eligibility Criteria:
Inclusion Criteria:

* T1DM,
* Male,
* basal-bolus regimen (insulin glargine / detemir with insulin lispro / aspart),
* HbA1c \< 9.9%,
* aged 18-50.

Exclusion Criteria:

* HbA1c \> 10%,
* not treated with basal-bolus (insulin glargine / detemir with insulin lispro / aspart),
* aged \<18 \> 50.
Community-Based Health Coach to Improve Access to Germline Genetic Testing Among African American Men With Prostate Cancer

This clinical trial studies barriers to genetic testing in African American men with prostate cancer and whether tailored, culturally relevant genetic testing education provided by a community-based health coach is beneficial in improving knowledge, attitudes, and awareness of genetic testing. Information gained from this study, may help researchers better understand and learn more about how to increase access to germline genetic testing in underrepresented populations.

PRIMARY OBJECTIVE:

I. To assess uptake of genetic testing using tailored education strategies and culturally relevant cancer resources delivered by a community-based health coach.

SECONDARY OBJECTIVE:

I. To assess decisional conflict among African American men receiving tailored education strategies and culturally relevant cancer resources on genetic testing delivered by a community-based health coach.

TERTIARY OBJECTIVE:

I. To assess the germline mutation rate among African American men with prostate cancer.

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT A: Patients complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may also undergo genetic testing.

COHORT B: Patients participate in educational session with health coach over 60 minutes. Patients also complete a survey about knowledge of, attitudes towards, and awareness of genetic testing and technology preferences and use over 30 minutes at baseline and over 20 minutes at exit or follow up. Patients may undergo genetic testing.

Eligibility Criteria:
Inclusion Criteria:

* Age \>= 18 years old
* Speak and read English
* Have no known cancer risk genetic mutation
* Self-identify as Black or African American
* Self-report a diagnosis of regional (lymph node positive), advanced, or metastatic prostate cancer per National Comprehensive Cancer Network (NCCN) guidelines

Exclusion Criteria:

* Prior germline genetic test
* Age \< 18 years old
* Unable to read or answer forms
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy

The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50 mg/d), administered for 12 wk, for patients with active moderate-severe Graves' Orbitopathy (GO).

Graves'orbitopathy is an autoimmune disease characterised by an inflammatory phase followed by fibrosis. Surgery to correct eyelid swelling, proptosis, and diplopia is effective, but can not be done until the inflammatory phase has passed. To arrest the inflammatory phase, several types of immunosuppressive treatments have been investigated. Corticosteroids are the first-choice immunosuppressive treatment, but they often cause severe side-effects.

Subantimicrobial dose doxycycline posses known anti-inflammatory effects that are separate from their antibacterial mode of action. This mode of action has lead to the routine use of subantimicrobial dose doxycycline for rosacea, periodontitis and multiple sclerosis.

We propose to test the effect of subantimicrobial dose doxycycline for non-sight threatening, moderate-severe, inflammatory GO.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of Graves' Orbitopathy
* Moderate-severe GO According to EUGOGO statements, patients with moderate-severe GO usually have any one or more of the following：moderate or severe soft tissue involvement, exophthalmos≥3mm above normal for race and gender, inconstant, or constant diplopia.
* Clinical activity score ≥ 3
* Being euthyroid for at least 1 month before the date of inclusion
* Must be able to swallow tablets
* Written informed consent is obtained

Exclusion Criteria:

* Mild Graves' Orbitopathy
* Sight-threatening Graves' Orbitopathy
* Clinical activity score \< 3
* Previous treatment for GO Oral steroids, intravenous steroids, radiotherapy
* Pregnant females as determined by positive (serum or urine) Human chorionic gonadotropin (hCG) test at screening or prior to dosing, or lactating females
* Uncontrolled diabetes or hypertension
* History of mental / psychiatric disorder
* Hepatic dysfunction (Albumin (Alb),Aspartate Transaminase (AST), Alanine Aminotransferase (ALT) and Alkaline phosphates levels must be within normal range for eligibility)
* Renal impairment (Urea and Creatinine levels must be within normal range)
* Doxycycline allergy or intolerance
Huaier Granule As Adjuvant Therapy for Colorectal Cancer After Radical Surgery

A randomized, paralleled control clinical study investigating Huaier Granule for prevention of recurrence and metastasis of colorectal cancer after radical surgery, to evaluate the efficacy and safety.


Eligibility Criteria:
Inclusion Criteria:

* The subjects volunteer to sign the informed consent;
* Aged: 18 to 75 years old;
* Colorectal cancer (AJCC-TNM, Stage Ⅰ, low-risk Stage Ⅱand Stage Ⅲ; Patients with Stage Ⅲ colorectal cancer refuse to postoperative adjuvant chemotherapy);
* The diagnosis and colorectal cancer has been confirmed by pathological examination after radical surgery;
* The liver and kidney function satisfies the following conditions within 15 days after surgery (excluding day 15): aspartate aminotransferase (AST), glutamic-oxalacetic transaminase (ALT), alkaline phosphatase (ALP)\< 2 upper limit of normal (ULN), total bilirubin ≤ 1.5 ULN, serum creatinine \< 1.5 ULN; normal coagulation function;
* Other laboratory tests meet the following requirements within 15 days after surgery (excluding day 15): white blood cells count ≥ 3.0×109/L, absolute neutrophil count ≥ 1.5×109/L, platelet count ≥ 100×109/L;
* ECOG：0-2 points；
* No other previous history of malignancy.

Exclusion Criteria:

* Multiple primary cancer;
* Not recover from the colorectal surgery;
* Presence of organ, bone, or skin metastases;
* Pregnant or lactating women;
* Those with active bleeding due to various reasons;
* Those with HIV infection or AIDS-associated diseases;
* Those with severe acute and chronic diseases;
* Those with severe diabetes;
* Those with serious infectious diseases;
* Those who can not take drugs by oral route;
* Drug abusers or those with psychological or mental diseases that may interfere with study compliance;
* Conditions that are considered not suitable for this study investigators.
Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori

This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori (H. pylori). A total of 162 patients with H. pylori infection were randomly assigned to either the 7-day triple therapy group (n = 81) or the bismuth plus triple therapy group (n = 81). The triple therapy (RAK) contained the twice-daily dosage of rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg. In the RBAK group, bismuth subcitrate 360 mg twice daily was added to the RAK regimen.

Once confirmed with H. pylori infection and having signed the informed consent, participants were randomly assigned to either the standard triple-therapy group (RAK: rabeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg, all twice daily for 7 days) or the bismuth plus standard triple-therapy group (RBAK: rabeprazole 20 mg, bismuth subcitrate 360 mg, amoxicillin 1 g and clarithromycin 500 mg, all twice daily for 7 days). A computer-generated random number was chosen for randomization. The patients and physicians were not blinded to the therapy assigned.

After completion of H. pylori eradication therapy, participants were asked to come back for collection of the information on any adverse event of drug compliance. In order to avoid false negative results, they were also asked to have a 4-week proton pump inhibitor, antibiotic and bismuth washout period before further examination of H. pylori status. The second endoscopy with rapid urea test, histology and culture or 13 C-urea breath test (UBT) for those who refused endoscopic exams was carried out at the end of the washout period. Those who did not return to confirm their H. pylori status were deemed as treatment failure in intention-to-treat (ITT) analysis.

Eligibility Criteria:
Inclusion Criteria:

1. male or non-pregnant female aged more than 20 y/r
2. H.pylori-infected
3. mental and legal ability to give a written informed consent

Exclusion Criteria:

1. allergy to any drug in the study
2. prior gastric surgery, severe concomitant diseases (e.g., decompensate liver cirrhosis, uremia, gastric cancer)
3. previous H. pylori eradication therapy
4. pregnancy or lactation.
Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC

A central challenge in the fight against breast cancer is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast cancer, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of breast cancer are urgently needed.

The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in breast cancer patients.


Eligibility Criteria:
Inclusion Criteria:

* Histological confirmed breast cancer subtypes (DCIS and invasive)

Exclusion Criteria:

* Pregnant women
* Minors (subjects less than 18 years of age)
* Prisoners
* Patients with known infectious disease, such as human immunodeficiency virus (HIV), tuberculosis (TB), or hepatitis B, C
* Patients having other than one cancer
* Subjects unable to consent for themselves
Vitamin D and Pregnancy: Camden Study

Vitamin D is present in food either naturally or by fortification and included in nutritional supplements. It is also synthesized photochemically by the skin from ultraviolet B radiation. Vitamin D synthesis varies by season and with latitude as well as according to intensity of skin pigmentation. Recent research in the United States found lower circulating levels of 25 (OH) D, the primary indicator of vitamin D status, among minority women who were either pregnant or in their reproductive years. The extent to which maternal vitamin D has an influence on the course and outcome of human pregnancy remains to be more completely studied. We propose to use the HPLC method to assay cholecaliferol (vitamin D3) and ergocalciferol (vitamin D2) to assess maternal vitamin D status. This will be accomplished by analyzing existing fasting samples and data derived from the 2001-2006 cohort (N=1141) of young, low income minority gravidae from Camden, New Jersey to determine:

1. The prognostic importance of maternal vitamin D status for birth weight, gestation duration and poor pregnancy outcomes (low birth weight, preterm delivery, fetal growth restriction).
2. The relation of maternal vitamin D status to important complications of pregnancy (gestational diabetes and pre-eclampsia).
3. The relationship of maternal vitamin D status to maternal diet and supplement use, season of year, ethnicity, overweight/obesity, and other maternal characteristics.


Eligibility Criteria:
Inclusion Criteria: Positive pregnancy test, informed consent, gestation at entry ≤20 weeks

Exclusion Criteria: Women with serious non-obstetric problems including lupus, type 1 or type 2 diabetes, seizure disorders, malignancies, acute or chronic liver or renal diseases, drug or alcohol abuse and psychiatric problems were not eligible for participation.
Protective Efficacy of HPV Vaccination After Treatment of HPV Related Diseases

To understand the HPV infection status and subtype distribution of patients, and to study the protective effect of prophylactic HPV vaccination on the recurrence of HPV related diseases after treatment through a prospective cohort study. To provide data support for the primary prevention of HPV related diseases in Chinese women after treatment, and to analyze the related factors of HPV related disease recurrence and HPV continuous positive.


Eligibility Criteria:
Inclusion Criteria:

* 1. Women aged 18-45, of childbearing age or before perimenopause (patients without pregnancy plan within two years); 2. Patients diagnosed as condyloma acuminatum, vaginal intraepithelial lesions (high-grade and low-grade lesions), cervical intraepithelial lesions (high-grade and low-grade lesions), vulvar intraepithelial lesions (high-grade and low-grade lesions), cervical cancer (IA1-IIA2 stage) and treated within 3 months; 3. No surgical contraindications such as severe center of heart, lung and other organ dysfunction and abnormal hemagglutination; 4. Fully know the treatment method, sign informed consent, and actively cooperate with follow-up.

Exclusion Criteria:

* 1. Participating in other clinical trials; 2. Use immunoglobulin or blood products within 3 months before vaccination; 3. Hypersensitivity to vaccine active ingredients or any dressing ingredients; 4. Acute stage of moderate and severe diseases; 5. Acute stage of severe immune deficiency diseases and autoimmune diseases; 6. Pregnant women and lactating patients; 7. Patients with planned pregnancy within 2 years; 8. Less than 18 years old and more than 45 years old.
Evaluation of One Burr Hole Evacuation for Subdural Hematoma

To evaluate the outcome of one burrhole evacuation for subdural hematoma and it has the same result of traditional two burrhole

* Subdural hematoma (SDH): abnormal Collection of Liquefied blood degradation underneath the dura matter (1.2.3).
* one of the most frequent types of intracranial haemorrhage, That is still associated with significant morbidity (1.4.5).
* The SDH: is a common disease in elderly Patient, and Its Incidence is highest in persons older than 70 Years of age (1.5).
* Types of Subdural hematoma(18.19)

  1- Acute: present within 48-72 hours of injury. 2. Sub-acute: manifest itself between 3-20 day. 3- Chronic (CH): produce symptoms from 3 weeks to several months after injury Risk Factors: (7.8.9.10.11.12)
  1. Trauma; mostly minor Trauma, Approximately two thirds of The Patients have suffered one. Reports exist of chronic SDH due to birth trauma in neonates.
  2. Advanced age: The elderly are at risk due to:

     1. brain atrophy, whereby The bridging veins are stretched and become more fragile.
     2. Older People tend to fall more often and Suffer minor head trauma.
     3. With increase age, The incidence of blood Thinner administration raises leading to increased risk for haemorrhage
  3. Chronic alcoholism:
  4. Gender: men, from all age groups, suffer higher rates of chsDH than woman.
  5. CoagulaPathy: Therapeutic anticoagulation and antiplatelet therapy.
  6. Medical Conditions: sepsis, hepatic failure, hemophilia, DIC and renal dialysis.
  7. Intracranial hypotension: as after ventriculoperitoneal shunt. clinical presentation (1.13)
* Symptoms of increase intra cranial pressure: Headache, Nausea, vomiting.
* Focal neurological deficit - (weakness, aphasia).
* Disturbed conscious level (DCL)
* Seizures
* Imaging investigation:

CT brain (14.15)

* Management : (1.6.16.17)

  1. Conservative: A watch, wait and re-scan Policy is usually recommended in asymptomatic or minimally symptomatic patient with a thin CHSDH.
  2. Surgical: For symptomatic (SDH) a- burr hole drainage B-twist drill drainage c- craniotomy
* prognostic factors : (2.5) 1- age of patient 2- Associated chronic diseases like hypertension, liver diseases .......Etc 3- Laboratory investigation like Hb , platlate count ,pc,and PT. 5- Hematoma thickness 6- number of burr hole : one or two burr hole

Eligibility Criteria:
Inclusion Criteria:

* Patients with subdural hematoma either unilateral or bilateral
* fit for surgery
* Chronic SDH
* Subacute SDH
* Age: patients older than 18 years old
* SEX: Both sex

Exclusion Criteria:

* Patients unfit for surgery
* Acute SDH
* subdural hyroma
* subdural empyema
* patient treated conservatively
Evaluation of a Treadmill Workstation in an Emergency Dispatch Center

The principal objective of this study is to determine if the provision of a treadmill workstation in an emergency medical services (EMS) dispatch center increases the number of steps that participants make daily within 6 months compared to the usual working conditions.

The investigators hypothesized that the provision of a treadmill workstation with a slow walking could increase the number of daily steps and decrease days of leave, musculoskeletal disorders without decreasing the dispatch quality.

Sedentariness, measured by the daily duration of time spent seated is a cardiovascular risk factor, chronic pathologies (cancer, musculoskeletal pain) and mortality.

The employees who remain seated from 8 to 11 hours per day have an increase risk of death within 3 years (15%). This increase reaches 40% for more than 11 hours a day.

The restoration of a daily moderate physical activity from 60 to 75 minutes could permit to eliminate this increased risk.

Interventions in workplace to limit sitting are associated with a metabolic benefit, but also with a reduction in musculoskeletal problems and fatigue.

The role of dispatchers is to initiate the medical record by determining the severity of the call and take rapid and adequate decision.

They are seated behind their desks from 8 to 11 hours in a busy and stressful environment.

Many dispatchers are complaining of musculoskeletal disorders and weight gain. An internal study conducted between between 2012 and 2016 showed an increase in long-term pain, irritability and sleep disorders. Overall, 65% of the respondents reported that they were tired at work and had less empathy.

The use of workstations with low-speed treadmills were assessed to allow physical activity at work.

A recent review concluded that their use reduced the time that the employees spent seated, stress and improved energy expenditure, as well as different biological and physical parameters (weight loss, lipid determination, glycaemia). This study did not reveal any alterations in performance at work.

The investigators assume that the establishment of a position allowing slow walk during dispatch call would increase the number of steps made by dispatchers on a daily basis and reduce the number of days of leave and musculoskeletal disorders, without impairing the quality of call pick-up.

Eligibility Criteria:
Inclusion Criteria:

* Dispatchers working in Emergency Medical Service

Exclusion Criteria:

* Pregnant women
* Inability to walk